JAMA: At least 95% of lung nodules are benign
- The Rise of Immunocell Therapy and the Era of “Farewell to Chemotherapy”
- Second Death Linked to Red Yeast Rice Supplement Reported in Japan
- Why Was Dementia Almost Nonexistent in Ancient Greece and Rome?
- Common Household Chemicals Pose Potential Threat to Brain Health
- Alarming Levels of Lead Detected in Chicago Tap Water
- Ribociclib Plus Endocrine Therapy Shows Promise in Early Breast Cancer
JAMA: At least 95% of lung nodules are benign
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- Japan: Over 10,000 Applications for Health Damage from COVID-19 Vaccines
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- ‘Elixir of Immortality’ Nicotinamide Riboside (NR) Virtually No Effect
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
JAMA: At least 95% of lung nodules are benign
Importance:
Pulmonary nodules are found in approximately 1.6 million patients each year in the United States, and can be detected in approximately 30% of chest computed tomography (CT) images.
Optimal treatment of individuals with lung nodules allows early detection of cancer while minimizing detection of benign nodules.
Observations:
At least 95% of pulmonary nodules are benign, most commonly granulomas or intrapulmonary lymph nodes. Smaller nodules are more likely to be benign. Lung nodules were classified as small solid (<8 mm), large solid (≥8 mm), and subsolid .
Subsolid nodules are divided into ground glass nodules (no solid component) and partially solid (both ground glass and solid components).
All nodules smaller than 6 mm have a less than 1% chance of malignancy, and 1% to 2% for nodules between 6 mm and 8 mm .
Nodules 6 to 8 mm can be repeated with chest CT in 6 to 12 months, depending on the presence of risk factors and imaging features associated with lung malignancy, clinical judgment of the probability of malignancy, and patient preference.
Treatment of individuals with solid pulmonary nodules 8 mm or larger is based on estimated probability of malignancy; presence of patient comorbidities, such as chronic obstructive pulmonary disease and coronary artery disease; and patient preference.
Management options include surveillance imaging, defined as monitoring of nodule growth by chest CT imaging, PET-CT imaging, nonsurgical biopsy using bronchoscopy or transthoracic needle biopsy, and surgical resection.
Partial solid pulmonary nodules are managed according to the size of the solid component. A larger solid fraction is associated with a higher risk of malignancy .
When ground-glass pulmonary nodules persist for more than 3 months and are larger than 10 mm in diameter, the probability of malignancy ranges from 10% to 50%.
Malignant nodules with a completely ground glass appearance usually grow slowly. Current bronchoscopy and transthoracic needle biopsy methods have a sensitivity of 70% to 90% for the diagnosis of lung cancer.
Conclusions and relevance:
Pulmonary nodules are found in approximately 1.6 million people in the United States each year, accounting for approximately 30% of chest CT images.
Treatment of patients with pulmonary nodules should be guided by the likelihood that the nodule is malignant, the safety of testing, the likelihood that additional testing will be informative, and patient preference.
JAMA: At least 95% of lung nodules are benign
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.